Entity
  • Temisis Therapeutics

    Created in 2018
  • BETA

    To investigate (B)
    Some signals may appear as inconsistent with a regular activity
  • Social networks

    401
  • Activities

  • Technologies

  • Entity types

  • Location

    19 Av. de la Forêt de Haye, 54500 Vandœuvre-lès-Nancy, France

    Vandœuvre-lès-Nancy

    France

  • Employees

    Scale: 2-10

    Estimated: 2

  • Engaged corporates

    4
    2 3
  • Added in Motherbase

    10 months, 3 weeks ago
Description
  • Value proposition

    Biotech developing novel first-in-class small-molecules to treat immuno-inflammatory diseases with high unmet needs

    “Temisis Therapeutics ("Temisis") is a pre-clinical stage biotechnology company developing innovative drugs derived from natural sources for the treatment of auto-immune and chronic inflammatory diseases, with an initial focus on psoriasis.

    Temisis most advanced compound, TEM-1657, a first-in-class and orally bioavailable small molecule, has demonstrated highly promising preclinical efficacy and safety profile in animal model of psoriasis, superior to Apremilast (Otezla TM), a Standard of Care (SOC) for patients with mild to moderate plaque psoriasis. In addition, TEM-1657 exhibited strong protective effect against Ulcerative Colitis (UC) in rodent, a form of Inflammatory Bowel Disease (IBD), which indicates this compound has therapeutic potential for other autoimmune/inflammatory diseases. TEM-1657 and its analogues act through a novel and breakthrough mechanism of action (MoA) downmodulating the release of key proinflammatory cytokines.

    Founded in December 2017, Temisis is based in Nancy and is a subsidiary of Plant Advanced Technologies ("PAT"), a plant-based biotechnology company specialized in the discovery and eco-friendly production of hard-to-source plant active extracts for the cosmetic, nutraceutical, agro-chemical and biotechnology markets.”

    biotechnology, dermatology, and semi-synthesis

  • Original language

    Biotech developing novel first-in-class small-molecules to treat immuno-inflammatory diseases with high unmet needs

    “Temisis Therapeutics ("Temisis") is a pre-clinical stage biotechnology company developing innovative drugs derived from natural sources for the treatment of auto-immune and chronic inflammatory diseases, with an initial focus on psoriasis.

    Temisis most advanced compound, TEM-1657, a first-in-class and orally bioavailable small molecule, has demonstrated highly promising preclinical efficacy and safety profile in animal model of psoriasis, superior to Apremilast (Otezla TM), a Standard of Care (SOC) for patients with mild to moderate plaque psoriasis. In addition, TEM-1657 exhibited strong protective effect against Ulcerative Colitis (UC) in rodent, a form of Inflammatory Bowel Disease (IBD), which indicates this compound has therapeutic potential for other autoimmune/inflammatory diseases. TEM-1657 and its analogues act through a novel and breakthrough mechanism of action (MoA) downmodulating the release of key proinflammatory cytokines.

    Founded in December 2017, Temisis is based in Nancy and is a subsidiary of Plant Advanced Technologies ("PAT"), a plant-based biotechnology company specialized in the discovery and eco-friendly production of hard-to-source plant active extracts for the cosmetic, nutraceutical, agro-chemical and biotechnology markets.”

  • Home - Temisis Therapeutics Focused on the development of novel and highly efficacious drugs for the treatment of inflammatory diseases
  • https://www.temisis.com/
Corporate interactions BETA
Corporate TypeTweets Articles
Communauté Urbaine du Grand Nancy
Communauté Urbaine du Grand Nancy
National and local authorities, Government Administration
Communauté Urbaine du Grand Nancy
National and local authorities, Government Administration
Other

31 Aug 2023


France Biotech
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
Other

22 Sep 2023


Bpifrance
Bpifrance
Bank, Banking
Bpifrance
Bank, Banking
Other

31 Jan 2023


BioValley France
BioValley France
Public business cluster, Biotechnology, French Cluster, Biotechnology Research
BioValley France
Public business cluster, Biotechnology, French Cluster, Biotechnology Research
Other

31 Jan 2023


Similar entities
Loading...
Loading...
Social network dynamics